Oral VEGFR-2 tyrosine kinase inhibitor (Pfizer study)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Oral VEGFR-2 tyrosine kinase inhibitor (Pfizer study), covering 2006-11-09 to 2006-11-09. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy [Phase 1, Phase 2]